Pulmokine
2007
FOUNDED
PRIVATE
STATUS
2ndary - Private
LATEST DEAL TYPE
3
INVESTORS
Description
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.
Website
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 7 University Place
- Room B127
- Rensselaer, NY 12144
- United States
+1 (518) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Pulmokine’s full profile, request a free trial.
Pulmokine Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 000 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2017 | 00000 | 000 | Completed | Generating Revenue | |
| 4. Grant | 01-Jan-2016 | 00.000 | 000 | Completed | Generating Revenue | |
| 3. Seed Round | 04-Mar-2015 | 000 | 000 | Completed | Generating Revenue | |
| 2. Debt - General | 01-Oct-2014 | Completed | Generating Revenue | |||
| 1. Grant | 27-Mar-2014 | $1.5M | Completed | Generating Revenue |
Pulmokine Investors (3)
Pulmokine Executive Team (5)
1 Former Executive
You’re viewing 4 of 5 executives. Get the full list »Pulmokine Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Shreefal Mehta Ph.D | Self | Board Director | 000 0000 |
1 Former Board Member
You’re viewing 1 of 2 board members. Get the full list »